Managing Primary Hyperparathyroidism When Parathyroidectomy Has Not Achieved Adequate Correction

Parathyroidectomy — surgical removal of neoplastic parathyroid tissue — is the definitive treatment for primary hyperparathyroidism. When surgery cannot be performed, is declined, or fails to achieve the expected correction, a structured medical management protocol is indicated.

This protocol applies to patients with primary hyperparathyroidism who are not surgical candidates, who decline surgery, or in whom parathyroidectomy has not achieved adequate disease control. These patients require a medical management approach targeting bone mineral density and calcium homeostasis.

Previous line — Parathyroidectomy: goals not achieved

Correction of hypercalcaemia with normalisation of serum calcium, and sustained improvement of bone mineral density.

Next-line approach — partial overview

Medical management focuses on anti-resorptive therapy directed at bone mineral density, with separate options available for patients with symptomatic hypercalcaemia, and a requirement to optimise vitamin D status. The full regimen — including agent selection, sequencing, and monitoring targets — is available in the complete structured protocol.

Treatment goals: Improvement in bone mineral density, and a vitamin D level above the recommended threshold.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/cen.14659

Patients who decline surgery or who are not considered surgical candidates may be considered for medical therapy such as anti‑resorptive therapies to treat osteoporosis, or the use of calcimimetic such as cinacalcet for the management of symptomatic hypercalcaemia.

Denosumab may also be considered as a suitable alternative to bisphosphonates in this setting.

It is important to ensure that these patients are vitamin D replete (i.e., vitamin D level >50 nmol/L).

Several studies have demonstrated the efficacy of bisphosphonates in improving BMD in this cohort.

View source ↗